EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Probing for peptidic drugs (2–10 kDa) in doping control blood samples

Andreas Thomas, Sam Thilmany, Amelie Hofmann, Mario Thevis

Analytical Science Advances · 2022-08 · 3 (7-8) · 235-243

DOI: 10.1002/ansa.202200027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Science Advances, online erschienen am 22.08.2022. Verfasst von Andreas Thomas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry, Center for Preventive Doping Research German Sport University Cologne Cologne Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bioactive peptides with a molecular mass between 2 and 10 kDa represent an important class of substances banned in elite sports, which has been recognized with an increasing number and variety of substances by anti‐doping organizations. Also, the annually renewed list of prohibited substances of the World Anti‐Doping Agency (WADA) explicitly mentions more and more of these peptides, and efficient testing procedures are required. Even under simplified sample preparation conditions, liquid chromatography coupled to high‐resolution mass spectrometry (with resolution properties > 100,000 full width at half maximum) offers suitable conditions for this task and can therefore be used as an initial testing procedure. In contrast to urine, blood analysis essentially relies on the detection of intact peptide hormones, and the expected concentrations are commonly higher in blood samples than in urine. This facilitates the analysis, and a generic sample preparation by means of mixed‐mode solid‐phase extraction could be realized in this study. Co‐extraction and analysis of several different peptides such as insulins (human, lispro, aspart, glulisine, tresiba, detemir, glargine, bovine insulin and porcine insulin), growth hormone releasing hormones (sermorelin, CJC‐1295 and tesamorelin), insulin‐like growth factors (long‐R 3 ‐IGF‐I, R 3 ‐IGF‐I and Des 1‐3 ‐IGF‐I) and mechano growth factors (human MGF and MGF‐Goldspink) with criteria that fulfil the requirements of the WADA documents (TD2022 MRPL) for doping controls. The proof of principle was shown by the analysis of post administration samples after treatment with synthetic insulin analogues.

Schlagwörter

Stichwörter der Autor:innen

LC‐MS/MShigh‐resolution mass spectrometrysports drug testing

Autor:innen und Institutionen

  • Institute of Biochemistry, Center for Preventive Doping Research German Sport University Cologne Cologne Germany.
  • European Monitoring Center for Emerging Doping Agents Cologne Germany.

Zitieren

APA

Thomas, A., Thilmany, S., Hofmann, A., & Thevis, M. (2022). Probing for peptidic drugs (2–10 kDa) in doping control blood samples. Analytical Science Advances, 3(7-8), 235-243. https://doi.org/10.1002/ansa.202200027

Vancouver

Thomas A, Thilmany S, Hofmann A, Thevis M. Probing for peptidic drugs (2–10 kDa) in doping control blood samples. Analytical Science Advances. 2022;3(7-8):235-243. doi:10.1002/ansa.202200027

BibTeX
@article{Thomas2022,
  author = {Thomas, Andreas and Thilmany, Sam and Hofmann, Amelie and Thevis, Mario},
  title = {Probing for peptidic drugs (2–10 kDa) in doping control blood samples},
  journal = {Analytical Science Advances},
  year = {2022},
  volume = {3},
  number = {7-8},
  pages = {235--243},
  doi = {10.1002/ansa.202200027}
}
Kostenlos starten →